NHS backs childhood X-linked hypophosphatemia (XLH) drug

The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Kyowa Kirin International’s Crysvita (burosumab) within its marketing authorisation,...

First personalised children’s cancer drug available on NHS

NHS England chief executive Simon Stevens has announced that children and young people in England will receive a ground-breaking cancer treatment, the first in...

Six new startups win funding and expert support from Bayer

Changing the experience of health: that’s the focus of the six startups which the Bayer G4A team has included in the Accelerator program this...

Azeria receives investment for cancer drug development

Azeria Therapeutics Limited, a newly formed drug discovery company, has announced that it has successfully raised £4 million in Series A fundraising from the...

Janssen’s multiple myeloma drug Darzalex®▼ approved

The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that the European Commission (EC) has granted marketing authorisation for Darzalex® (daratumumab) for use...

Multiple sclerosis drug shown to slow brain shrinkage by half

A promising drug slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half, according to new research led by Cleveland Clinic. Very limited...

Cablivi approved for acquired thrombotic thrombocytopenic purpura (aTTP)

The European Commission has granted marketing authorisation for Cablivi (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP),...

Alnylam receives approval of RNAi therapeutic ONPATTRO

Alnylam Pharmaceuticals has announced that the European Commission (EC) has granted marketing authorisation for ONPATTRO ™ (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR)...

New HIV drugs DELSTRIGO & PIFELTRO approved by FDA

Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has approved two new...

PatSnap Bio, used to screen 300 million DNA and RNA sequences

PatSnap, a provider of research and development (R&D) analytics, has announced the launch of PatSnap Bio, a new module to the PatSnap platform that...

Latest articles

launch of flutiform® k-haler® for UK asthma patients

Napp Pharmaceuticals Limited has announced that flutiform k-haler is now available for adults and adolescents living with asthma, where the use of a combination...

Calls for NICE to overturn decision on MS drug ocrelizumab

The first and only licensed disease-modifying treatment ocrelizumab, for people with early Primary-Progressive Multiple Sclerosis PPMS will not be made available on the NHS. In...

Pharmaceutical job opportunities: Star recruits for ground-breaking product launch

Star, the UK's first choice outsourcing and resourcing provider to the pharmaceutical, medical device and healthcare industries is delighted to announce a new partnership. Through...